2022
Genetic testing in privately insured women with surgically treated breast cancer
Dinan M, Pitafi S, Greenup R, Long J, Gross C. Genetic testing in privately insured women with surgically treated breast cancer. Breast Cancer Research And Treatment 2022, 198: 177-181. PMID: 36542252, DOI: 10.1007/s10549-022-06829-4.Peer-Reviewed Original ResearchConceptsBreast cancerGenetic testingRoutine breast cancer careBRCA1/BRCA2 genetic testingHormone receptor statusBreast cancer careInvasive breast cancerBRCA2 genetic testingReceptor statusWomen 50Cancer careAge 45Family historyOlder womenInsurer databaseYoung womenCancerWomenCoverage policiesUnclear implicationsPatientsSurgeryPurposeRatesYearsPrevalence
2004
Cancer Trial Enrollment After State-Mandated Reimbursement
Gross CP, Murthy V, Li Y, Kaluzny AD, Krumholz HM. Cancer Trial Enrollment After State-Mandated Reimbursement. Journal Of The National Cancer Institute 2004, 96: 1063-1069. PMID: 15265967, DOI: 10.1093/jnci/djh193.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicColorectal NeoplasmsFemaleGovernment RegulationHumansIncidenceLogistic ModelsLongitudinal StudiesLung NeoplasmsMaleMulticenter Studies as TopicNational Institutes of Health (U.S.)NeoplasmsPatient SelectionPoisson DistributionProstatic NeoplasmsReimbursement MechanismsRetrospective StudiesState GovernmentUnited StatesConceptsCancer trial enrollmentTrial enrollment ratesTrial enrollmentMultivariable analysisTrial participationOdds ratioTrial participantsCoverage policiesCancer trial participantsCooperative group trialsClinical trial enrollmentEarly phase trialsRecruitment of patientsCancer trial participationMedical care costsPhase II trial participantsCancer patientsPhase trialsCancer research studiesGroup trialsCare costsPoisson regressionCancer typesReimbursement policiesPhase II
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply